FIELD: immunology, biotechnology, medicine.
SUBSTANCE: invention relates to antiidiotypical monoclonal antibody or fragment thereof for BSW17 antibody effecting on LgE Cε3-region bonding to high affinity LgE receptor. Amino acid sequence is as described in specification. antiidiotypical antibody is useful as pharmaceutical composition ingredient for LgE-mediated disease treatment. Invention make in possible to prevent allergic disorders and inflammations due to inhibiting interaction between LgE Cε3-region with high affinity receptor by claimed antibody.
EFFECT: new agent for allergic and inflammation disorder treatment.
7 cl, 32 dwg, 5 tbl, 10 ex
Title | Year | Author | Number |
---|---|---|---|
RECOMBINANT ANTIBODY IL4 USED FOR TREATMENT OF DISORDERS ASSOCIATED WITH FUNCTION OF IL4 | 1994 |
|
RU2162711C2 |
HUMAN ONCOSTATIN M ANTIBODIES AND METHODS OF USE THEREOF | 2011 |
|
RU2600444C2 |
ANTIBODY AGAINST IL-4R AND APPLICATION THEREOF | 2018 |
|
RU2758091C1 |
MONOCLONAL ANTIBODY TO HUMAN INTERFERON BETA-1A | 2018 |
|
RU2728696C2 |
NOVEL ANTI-IL13 ANTIBODIES AND USE THEREOF | 2004 |
|
RU2487887C2 |
ANTIBODIES SPECIFIC TO CD47 AND PD-L1 | 2020 |
|
RU2779652C2 |
MONOCLONAL ANTIBODY TO IL-5RΑ | 2017 |
|
RU2698048C2 |
ANTIBODY FOR BLyS | 2013 |
|
RU2613422C2 |
MONOCLONAL ANTIBODY, BINDING WITH EBOLA VIRUS GLYCOPROTEIN, DNA FRAGMENTS CODING THIS ANTIBODY, AND ANTIGEN-BINDING FRAGMENT | 2015 |
|
RU2639533C2 |
MONOCLONAL ANTIBODY CAPABLE OF NEUTRALIZING BIOLOGICAL ACTIVITY OF HUMAN INTERFERON BETA 1A | 2018 |
|
RU2729391C2 |
Authors
Dates
2005-06-10—Published
2000-04-12—Filed